{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T18:24:47Z","timestamp":1747765487217},"reference-count":7,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund OnabotulinumtoxinA (Botox) ist in Deutschland seit\n      2013 nach Versagen einer anticholinergen Therapie f\u00fcr die Second-line Behandlung der\n      idiopathischen \u00fcberaktiven Harnblase als Detrusorinjektion (OnabotA-DI) zugelassen. Bis 2018\n      f\u00fchrten jedoch abrechnungstechnische H\u00fcrden dazu, dass die Anwendung weit hinter dem Bedarf\n      zur\u00fcckblieb. Seit Anfang 2018 gibt es nun in Deutschland eine EBM-Zulassungsziffer f\u00fcr die\n      transurethrale Anwendung von Botox in der Urologie.<\/jats:p><jats:p>\n          Fragestellung\n      Ziel einer Umfrage 2019 unter Kursteilnehmern regelm\u00e4\u00dfig stattfindender Injektions-Workshops\n      (WS-T) in unserer Institution war es zu evaluieren, ob die Abrechenbarkeit das\n      Anwenderverhalten in Deutschland bedarfsgerecht ver\u00e4ndert hat. Eine gleiche Umfrage 2021\n      sollte Entwicklungen der vergangenen zwei Jahre aufzeigen.<\/jats:p><jats:p>\n          Material und\n        Methoden 88 konsekutive TeilnehmerInnen eines seit 2013 regelm\u00e4\u00dfig stattfindenden\n      Anwender- Workshops wurden im Jahre 2019 per Fragebogen anonym bzgl. der bei ihnen\n      durchgef\u00fchrten Praxis der OnabotA-DI befragt. Die Befragung wurde 2021 nochmals in einer\n      anonymisierten Online-Umfrage bei 55 Kursteilnehmern wiederholt, um Ver\u00e4nderungen des\n      Anwenderverhaltens der vergangenen zwei Jahre zu evaluieren.<\/jats:p><jats:p>\n          Ergebnisse Evaluation 2019: R\u00fccklaufquote 35\/88 der Frageb\u00f6gen (39,8%); eine gro\u00dfe\n      Mehrheit (82%) der WS-T hatten erst NACH der Einrichtung der EBM-Ziffer den Workshop besucht.\n      Ldgl. 54,5% der WS-T f\u00fchrten nach dem Workshop zwei oder mehr (12% mehr als zehn) OnabotA-DI\n      pro Quartal durch. Die meisten der Anwender (85%) f\u00fchrten den Eingriff immer oder weit\n      \u00fcberwiegend ambulant, 63% immer oder weit \u00fcberwiegend in Lokalan\u00e4sthesie durch. Die Mehrheit\n      (84%) verabreichte keine oder lediglich eine perioperative Antibiose, 13% \u00fcber eine Woche. 89%\n      gaben an, dass mind. 70% ihrer PatientInnen keine oder nur leichte Beschwerden unter der LA\n      hatten. In der Evaluation 2021 f\u00fchrten die Anwender den Eingriff tendenziell h\u00e4ufiger ambulant\n      und in LA sowie h\u00e4ufiger ganz ohne Antibiotikagaben durch.<\/jats:p><jats:p>\n          Schlussfolgerungen Die Ergebnisse unserer Anwenderumfrage deuten darauf hin, dass\n      die Durchf\u00fchrung der OnabotA-DI seit der EBM-Zulassung in Deutschland im Januar 2018\n      wesentlichen Aufwind gewonnen hat. Der Eingriff l\u00e4sst sich in der \u00fcberwiegenden Zahl\n      unkompliziert ambulant in Lokalan\u00e4sthesie durchf\u00fchren. <\/jats:p>","DOI":"10.1055\/a-1924-7517","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T23:13:25Z","timestamp":1666134805000},"page":"55-60","source":"Crossref","is-referenced-by-count":2,"title":["OnabotuliumtoxinA Detrusorinjektion: Die \u201eReal World\u201d der Anwender, die \u201eReal World\u201c der Patienten \u2013  Update BOTUROLOGY 2022"],"prefix":"10.1055","volume":"54","author":[{"given":"Heinrich","family":"Schulte-Baukloh","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Urologische Gemeinschaftspraxis, Berlin-Mitte\/Moabit, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"H\u00f6ppner","sequence":"additional","affiliation":[{"name":"Urologische Gemeinschaftspraxis, Berlin-Mitte\/Moabit, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Hubatsch","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Mala","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Schlomm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Weinberger","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"DE Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","article-title":"OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial","volume":"197","author":"VW Nitti","year":"2017","journal-title":"The Journal of Urology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00192-020-04423-0","article-title":"OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice","volume":"32","author":"R Hamid","year":"2021","journal-title":"Int Urogynecol J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s00120-014-3658-2","article-title":"Use of botulinum toxin type A in non-neurogenic overactive bladder. Recommendations of the Working Group Urological Functional Diagnostics and Urology in Women","volume":"54","author":"RM Bauer","year":"2015","journal-title":"Urologe A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/nau.24519","article-title":"Alkalinized lidocaine solution as a first-line local anesthesia protocol for intradetrusor injection of onabotulinum toxin A: Results from a double-blinded randomized controlled trial","volume":"39","author":"ESR Pereira","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bjid.2016.08.012","article-title":"Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A","volume":"20","author":"AC Paradella","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"33197","DOI":"10.1038\/srep33197","article-title":"Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity","volume":"6","author":"L Leitner","year":"2016","journal-title":"Sci Rep"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1924-7517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:23:33Z","timestamp":1676420613000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1924-7517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":7,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,2,14]]},"published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1924-7517","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]}}}